Skip to main content
SpringerLink
Log in

Magic bullet

  • Chapter
Köhler’s Invention

  • 246 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Chapter 16

  • Isaacs, A., Lindenmann, J. 1987 (reprinted). Virus interference. I. The interferon. 1957. J Interferon Res. 7:429.

    PubMed  CAS  Google Scholar 

  • Peters, T. 1993. Interferon and its first clinical trial: Looking behind the scenes. Medical History 37: 270.

    Google Scholar 

  • Secher, D.S., Burke, D.C. 1980. A monoclonal antibody for large-scale purification of human leukocyte interferon. Nature 285:446.

    Article  PubMed  CAS  Google Scholar 

  • Mountain, A., Ney, U., Schomburg, D. Eds. 1999. Biotechnology 2nd Ed. Volume 5a. Recombinant proteins, monoclonal antibodies, and therapeutic genes. Wiley-VCH. Weinheim.

    Google Scholar 

  • Bullok, D. 1983. Diagnostic and biochemical applications: Monoclonal antibodies. Biotechnology Advances 84: 81.

    Google Scholar 

  • Payne, W.J., Marshall, D.L., Shockley, R.K., Martin, W.J. 1988. Clinical laboratory applications of monoclonal antibodies. J. Immunol. Meth. 116: 151.

    Google Scholar 

  • Chein, S., Silverstein, S.C. 1993. Economic impact of application of monoclonal antobodies to medicine and biology. The FASEB J. 7:1426.

    Google Scholar 

  • World market for monoclonal anitibodies 2001–2010. 2004. TriMark Publications, New York. http://trimarkpublications.ecnext.com

    Google Scholar 

  • Monoclonal antibodies 2003: Meeting clinical and financial expectations. 2004. Lead discovery services, UK. http://www.leaddiscovery.co.uk.

    Google Scholar 

  • Fjermedal. 1984. Magic bullets. Macmillan, New York.

    Google Scholar 

  • Berkower, I. 1996. The promose and pitfalls of monoclonal antibody therapeutics. Curr. Op. Biotech. 7:622.

    Article  CAS  Google Scholar 

  • Winter, G., Milstein, C. 1991. Man-made antibodies. Nature 349:293.

    Article  PubMed  CAS  Google Scholar 

  • Morrison, S.L. 1992. In vitro antibodies: Strategies for production and application. Ann. Rev. Immunol. 10:239.

    Article  CAS  Google Scholar 

  • Grillo-Lopez, J. Ed. 2001. Monoclonal antibodies in the treatment of hematologic malignancies. In: Current Pharmaceutical Biotechnology, Vol.2. Bentham Science Publ.

    Google Scholar 

  • Weiner, G.J., Link, B.K. 2004. Antibody therapy of lymphoma. Adv. Pharmacol. 51:229.

    PubMed  CAS  Google Scholar 

  • Knight, C., Hind, D., Brewer, N., Abbott, V. 2004. Rituximab (MabThera) for aggressive non-Hodgkin’s lymphoma: systematic review and economic evaluation. Health Technol. Assess. 8: 1.

    Google Scholar 

  • Hillmen, P. 2004. Advancing therapy for chronic lymphocytic leukemia-the role of rituximab. Semin. Oncol. 31(1 Suppl 2):22.

    PubMed  CAS  Google Scholar 

  • Dechant, M., Bruenke, J., Valerius, T. 2003. HLA class II antibodies in the treatment of hematologic malignancies. Semin. Oncol. 30:465.

    Article  PubMed  CAS  Google Scholar 

  • Ghobrial, I., Witzig, T. 2004. Radioimmunotherapy: a new treatment modality for B-cell non-Hodgkin’s lymphoma. Oncology 18:623.

    PubMed  Google Scholar 

  • Linenberger, M.L. 2005. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia 19:176.

    Article  PubMed  CAS  Google Scholar 

  • Ravandi, F., O’Brien, S. 2005. Alemtuzumab. Expert Rev. Anticancer Ther. 5:39.

    Article  PubMed  CAS  Google Scholar 

  • Dearden, C. 2004. Alemtuzumab in peripheral T-cell malignancies. Cancer Biother. Radiopharm. 19:391.

    PubMed  CAS  Google Scholar 

  • Kataoka, A., Ishidam, M., Murakamim, S., Ohnom S. 2004. Sensitization of chemotherapy by anti-HER. Breast Cancer 11:105.

    Article  PubMed  Google Scholar 

  • Bell, R., Verma, S., Untch, M., Cameron, D., Smith, I. 2004. Maximizing clinical benefit with trastuzumab. Semin. Oncol. 31(5 Suppl 10):35.

    PubMed  CAS  Google Scholar 

  • Emens, L.A., Davidson, N.E. 2004. Trastuzumab in breast cancer. Oncology 18:1117.

    PubMed  Google Scholar 

  • Ng, M., Cunningham, D. 2004. Cetuximab (Erbitux) — an emerging targeted therapy for epidermal growth factor receptor-expressing tumours. Int. J. Clin. Pract. 58:970.

    Article  PubMed  CAS  Google Scholar 

  • Baumann, M., Krause, M. 2004. Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. Radiother. Oncol. 72:257.

    Article  PubMed  CAS  Google Scholar 

  • Camp-Sorrell, D. 2003. Antiangiogenesis: the fifth cancer treatment modality? Oncol. Nurs. Forum. 30:934.

    PubMed  Google Scholar 

  • Glade-Bender, J., Kandel, J.J., Yamashiro, D.J. 2003. VEGF blocking therapy in the treatment of cancer. Expert Opin. Biol. Ther. 3:263.

    Article  PubMed  CAS  Google Scholar 

  • Franson, P.J., Lapka, D.V. 2005. Antivascular endothelial growth factor monoclonal antibody therapy: a promising paradigm in colorectal cancer. Clin. J, Oncol. Nurs. 9:55.

    Google Scholar 

  • Iqbal, S., Lenz. H-J. 2004. Angiogenesis inhibitors in the treatment of colorectal cancer. Semin. Oncol. 31(6 Suppl 17):10.

    PubMed  CAS  Google Scholar 

  • Roberts, L., McColl, G.J. 2004. Tumour necrosis factor inhibitors: risks and benefits in patients with rheumatoid arthritis. Intern. Med. J. 34:687.

    PubMed  CAS  Google Scholar 

  • Sands, B.E. 2004. Why do anti-tumor necrosis factor antibodies work in Crohn’s disease? Rev. Gastroenterol Disord. 4(Suppl 3):10.

    Google Scholar 

  • Ehlers, S. 2005. Why does tumor necrosis factor targeted therapy reactivate tuberculosis? J. Rheumatol. 74:35.

    CAS  Google Scholar 

  • Buhl, R. 2005. Anti-IgE antibodies for the treatment of asthma. Curr. Opin. Pulm. Med. 11:27.

    PubMed  CAS  Google Scholar 

  • Bang, L.M., Plosker, G.L. 2004. Spotlight on omalizumab in allergic asthma. BioDrugs 18:415.

    PubMed  Google Scholar 

  • Van Gelder, T., Warle, M., Ter Meulen, R.G. 2004. Anti-interleukin-2 receptor antibodies in transplantation: what is the basis for choice? Drugs 64:1737.

    PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Birkhäuser Verlag

About this chapter

Cite this chapter

(2005). Magic bullet. In: Köhler’s Invention. Birkhäuser Basel. https://doi.org/10.1007/3-7643-7413-6_16

Download citation

Publish with us

Policies and ethics

Search

Navigation